Expanding the chemical diversity of CK2 inhibitors

Molecular and Cellular Biochemistry

Volumn 316, Issue 1-2, 2008, Pages 71-85

  Prudent, Renaud ^a,b,c   Moucadel, Virginie ^a,b,c   López Ramos, Miriam ^d,e,f   Aci, Samia ^b   Laudet, Beatrice ^a,b,c   Mouawad, Liliane ^d,f   Barette, Caroline ^b   Einhorn, Jacques ^g   Einhorn, Cathy ^g   Denis, Jean Noel ^g   Bisson, Gilles ^h   Schmidt, Frédéric ^d,e   Roy, Sylvaine ^b   Lafanechere, Laurence ^b   Florent, Jean Claude ^d,e   Cochet, Claude ^a,b,c  

^a INSERM   (France)

^b CEA GRENOBLE   (France)

^c UNIV GRENOBLE ALPES   (France)

^d INSTITUT CURIE   (France)

^e CNRS   (France)

^f Centre Universitaire   (France)

^g UNIVERSITÉ JOSEPH FOURIER   (France)

^h LABORATOIRE TIMC IMAG   (France)

Author keywords

CK2; Kinase inhibitors; Non competitive

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; BOSUTINIB; CASEIN KINASE II INHIBITOR; DASATINIB; EMODIN; IMATINIB; INDIRUBINE 3' MONOXIME; MITOXANTRONE; N HYDROXYPHTHALIMIDE DERIVATIVE; NILOTINIB; PROTEIN SERINE THREONINE KINASE INHIBITOR; STIBONIC ACID DERIVATIVE; XANTHENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INFORMATION PROCESSING; LUNG CARCINOMA; MOLECULAR DOCKING; PROSTATE CARCINOMA; STRUCTURE ACTIVITY RELATION; UTERINE CERVIX CARCINOMA;

EID: 50649107702     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-008-9828-z     Document Type: Article

References (42)

1. Wang H, Davis A, Yu S, Ahmed K (2001) Response of cancer cells to molecular interruption of the CK2 signal. Mol Cell Biochem 227:167-174. doi: 10.1023/A:1013112908734
2. Unger GM, Davis AT, Slaton JW, Ahmed K (2003) Protein kinase CK2 as regulator of cell survival: Implications for cancer therapy. Curr Cancer Drug Targets 4:77-84. doi: 10.2174/1568009043481687
3. Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K (2004) Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res 2:712-721
4. Battistutta R, De Moliner E, Sarno S, Zanotti G, Pinna LA (2001) Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Protein Sci 10:2200-2206. doi: 10.1110/ps.19601
5. Golub AG, Yakovenko OY, Bdzhola VG, Sapelkin VM, Zien P, Yarmoluk SM (2006) Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J Med Chem 49:6443-6450. doi: 10.1021/jm050048t
6. Battistutta R, Mazzorana M, Sarno S, Kazimierczuk Z, Zanotti G, Pinna LA (2005) Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole. Chem Biol 12:1211-1219. doi: 10.1016/j.chembiol.2005.08.015
7. Nie Z, Perretta C, Erickson P, Margosiak S, Almassy R, Lu J et al (2007) Structure-based design, synthesis, and study of pyrazolo[1, 5-a][1, 3, 5]triazine derivatives as potent inhibitors of protein kinase CK2. Bioorg Med Chem Lett 17:4191-4195. doi: 10.1016/j.bmcl.2007.05.041
8. Li M, Allen A, Smith TJ (2007) High throughput screening reveals several new classes of glutamate dehydrogenase inhibitors. Biochemistry 46:15089-15102. doi: 10.1021/bi7018783
9. Duncan JS, Gyenis L, Lenehan J, Bretner M, Graves LM, Haystead TA et al (2008) An unbiased evaluation of CK2 inhibitors by chemo-proteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol Cell Proteomics; Epub ahead of print
10. Bogoyevitch MA, Fairlie DP (2007) A new paradigm for protein kinase inhibition: Blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 12:622-633. doi: 10.1016/j.drudis.2007.06.008
11. Heriche JK, Lebrin F, Rabilloud T, Leroy D, Chambaz EM, Goldberg Y (1997) Regulation of protein phosphatase 2A by direct interaction with casein kinase 2alpha. Science 276:952-955. doi: 10.1126/ science.276.5314.952
12. Filhol O, Cochet C, Chambaz EM (1990) Cytoplasmic and nuclear distribution of casein kinase II characterization of the enzyme uptake by bovine adrenocortical nuclear preparation. Biochemistry 29:9928-9936
13. SYBYL, version 6.9; Tripos Inc. (1699 South Hanley Road, St. Louis, MO, 63144)
14. FlexX, Version 1.13.5; Sankt Augustin, Germany BioSolveIT GmbH
15. Steinbeck C, Han Y, Kuhn S, Horlacher O, Luttmann E, Willighagen E (2003) The Chemistry Development Kit (CDK) an open-source Java library for chemo- and bioinformatics. J Chem Inf Comput Sci 43:493-500. doi: 10.1021/ci025584y
16. Steinbeck C, Hoppe C, Kuhn S, Floris M, Guha R, Willighagen EL (2006) Recent developments of the chemistry development kit (CDK) - an open-source java library for chemo- and bioinformatics. Curr Pharm Des 12:2111-2120 doi: 10.2174/138161206777585274
17. Gasteiger J, Engel T (2004) Chemoinformatics: A textbook. Wiley. ISBN 3-527-30681-1
18. Viswanadhan VN, Ghose AK, Revankar GR, Robins RK (1989) Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 29:163-172. doi: 10.1021/ci00063a006
19. Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714-3717. doi: 10.1021/jm000942e
20. Wiener H (1947) Structural determination of paraffin boiling points. J Am Chem Soc 69:17-20. doi: 10.1021/ja01193a005
21. Randic M (1975) On characterization of molecular branching. J Am Chem Soc 97:6609-6615. doi: 10.1021/ja00856a001
22. Sharma V, Goswami R, Madan AK (1997) Eccentric Connectivity Index: A novel highly discriminating topological descriptor. J Chem Inf Comput Sci 37:273-282. doi: 10.1021/ci960049h
23. Eibe F, Witten IH (1998) generating accurate rule sets without global optimization. In: Fifteenth International Conference on Machine Learning, pp 144-151
24. Lin XC, Liu XG, Chen XW, Chen WZ, Liang NC (2004) Inhibitory effect and its kinetic analysis of baicalein on recombinant human protein kinase CK2 holoenzyme. Ai Zheng 23:874-878
25. Soto J, Berman J (2006) Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 100(Suppl 1):S34-S40. doi: 10.1016/j.trstmh.2006.02.022
26. Pagano MA, Poletto G, Di Maira G, Cozza G, Ruzzene M, Sarno S et al (2007) Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. ChemBioChem 8:129-139. doi: 10.1002/cbic.200600293
27. Golub AG, Yakovenko OY, Prykhod'ko AO, Lukashov SS, Bdzhola VG, Yarmoluk SM (2008) Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1, 3(2H)-diones as inhibitors of human protein kinase CK2. Biochim Biophys Acta 1784:143-149
28. Novac O, Guenier AS, Pelletier J (2004) Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. Nucleic Acids Res 32:902-915. doi: 10.1093/nar/gkh235
29. Tan YJ, Teng E, Ting AE (2003) A small inhibitor of the interaction between Bax and Bcl-X(L) can synergize with methylprednisolone to induce apoptosis in Bcl-X(L)-overexpressing breast-cancer cells. J Cancer Res Clin Oncol 129:437-448. doi: 10.1007/s00432-003-0464-4
30. Chin PC, Liu L, Morrison BE, Siddiq A, Ratan RR, Bottiglieri T et al (2004) The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J Neurochem 90:595-608. doi: 10.1111/ j.1471-4159.2004.02530.x
31. Zhen Y, Sorensen V, Jin Y, Suo Z, Wiedlocha A (2007) Indirubin-3′-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK. Oncogene 26:6372-6385. doi: 10.1038/sj.onc.1210473
32. Perabo FG, Frossler C, Landwehrs G, Schmidt DH, von Rucker A, Wirger A et al (2006) Indirubin-3′-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer. Anticancer Res 26:2129-2135
33. Lee JW, Moon MJ, Min HY, Chung HJ, Park EJ, Park HJ et al (2005) Induction of apoptosis by a novel indirubin-5-nitro-3′-monoxime, a CDK inhibitor, in human lung cancer cells. Bioorg Med Chem Lett 15:3948-3952. doi: 10.1016/j.bmcl.2005.05.105
34. Xie Y, Liu Y, Ma C, Yuan Z, Wang W, Zhu Z et al (2004) Indirubin-3′-oxime inhibits c-Jun NH2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Neurosci Lett 367:355-359. doi: 10.1016/j.neulet.2004.06.044
35. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98:13681-13686. doi: 10.1073/pnas.251194298
36. Koceva-Chyla A, Jedrzejczak M, Skierski J, Kania K, Jozwiak Z (2005) Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: Relation to drug cytotoxicity and caspase-3 activation. Apoptosis 10:1497-1514. doi: 10.1007/s10495-005-1540-9
37. Moen MD, McKeage K, Plosker GL, Siddiqui MA (2007) Imatinib: A review of its use in chronic myeloid leukaemia. Drugs 67:299-320. doi: 10.2165/ 00003495-200767020-00010
38. Nicolini FE, Chabane K, Tigaud I, Michallet M, Magaud JP, Hayette S (2007) BCR-ABL mutant kinetics in CML patients treated with dasatinib. Leuk Res 31:865-868. doi: 10.1016/j.leukres.2006.12.003
39. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540-3546. doi: 10.1182/blood-2007-03-080689
40. Boschelli DH, Wu B, Ye F, Wang Y, Golas JM, Lucas J et al (2006) Synthesis and Src kinase inhibitory activity of a series of
41. Regev R, Yeheskely-Hayon D, Katzir H, Eytan GD (2005) Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism. Biochem Pharmacol 70:161-169. doi: 10.1016/j.bcp. 2005.03.032
42. Humphrey W, Dalke A, Schulten K (1996) VMD - Visual Molecular Dynamics. J Mol Graph 14:33-38. doi: 10.1016/0263-7855(96)00018-5